Skip to content

HedgeWeek-AIMA Mid-Year Allocator Sentiment Report 2025

This report, produced by Hedgeweek and sponsored by AlphaSense, summarises the surprising findings from a survey of nearly 100 global allocators in the first half of 2025. Despite geopolitical volatility, investors are displaying renewed optimism towards hedge funds.

The report highlights two key trends:

  1. Part I: Renewed Optimism
  2. Nearly half of the surveyed allocators plan to increase their hedge fund allocations.
  3. They are actively seeking new partnerships to capitalize on volatility and are raising their return expectations.
  4. The report details strategy preferences and regional shifts, particularly from institutions in APAC and the Middle East.
  5. Part II: Structural Shifts
  6. This section explores how allocators are viewing geopolitical tension as a strategic opportunity rather than a risk.
  7. It also examines changes in fee dynamics, the growing popularity of Separately Managed Accounts (SMAs), and other alternative investments.

The report includes an interview with Yashar Jedari from AlphaSense, who discusses how AI-powered research tools are enabling hedge fund managers to efficiently navigate this complex environment and level the playing field for smaller firms.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.